Latest Healthcare News

Cleo Diagnostics (ASX:COV) has hit a major milestone by completing sample collection for its pivotal U.S. ovarian cancer trial, while progressing manufacturing and analytical validation steps toward FDA 510(k) submission.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Resonance Health reports strong cash flow and progress in clinical trials, with a record forward order pipeline for its Software-as-a-Medical-Device business and profitable trial site clinics.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

CONNEQT Health’s Pulse device sales surged to a $7 million annualised run-rate despite a temporary supply hiccup, while the company manages a tight cash runway supported by new R&D loans and related-party funding.